鉴别局灶性结节性增生与肝细胞腺瘤诊断策略的成本效果分析
该研究构建决策树模型,比较钆塞酸二钠增强MRI、传统MRI和活检作为初始诊断方式在偶发局灶性肝病变疑为FNH或HCA患者中的成本效果。三种策略的诊断成功率相似,而钆塞酸二钠增强MRI策略在美国和韩国的成本均最低,敏感性分析结果不变,结论为其最具成本效果。
要点
- 三种策略诊断FNH与HCA的成功率相似。
- 钆塞酸二钠增强MRI策略成本最低。
- 钆塞酸二钠增强MRI是鉴别FNH与HCA最具成本效果的策略。
核心结论
- 在非肝硬化肝内偶发局灶性病变患者中,钆塞酸二钠增强MRI策略是鉴别FNH与HCA最具成本效果的策略。
研究设计与样本
- 决策树模型,比较钆塞酸二钠增强MRI、传统细胞外对比剂MRI和活检作为初始诊断方式的成本效果。
诊断标准与关键数值
- 成本基于美国和韩国的使用率与Medicare报销标准;钆塞酸二钠增强MRI策略成本美国1283美元、韩国813美元,活检策略美国1725美元、韩国847美元,传统MRI策略美国1750美元、韩国962美元。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We evaluated the cost-effectiveness of a gadoxetic acid-enhanced MRI (EOB-MRI) strategy compared with conventional MRI strategy and biopsy to differentiate focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA).
METHODS: A decision tree model was constructed to compare the cost-effectiveness of EOB-MRI, conventional MRI with extracellular contrast agents, and biopsy as the initial diagnostic modality in patients with incidentally detected focal liver lesions suspected of being FNH or HCA. We analysed the cost and effectiveness, i.e. probability of successful diagnosis of each strategy. Costs were based on utilisation rates and Medicare reimbursements in the USA and South Korea.
RESULTS: In the base case analysis of our decision tree model, the effectiveness of the three strategies was similar. The cost of the EOB-MRI strategy ($1283 in USA, $813 in South Korea) was lowest compared with the biopsy strategy ($1725 in USA, $847 in South Korea) and the conventional MRI strategy ($1750 in USA, $962 in South Korea). One-way, two-way and probabilistic sensitivity analysis showed unchanged results over an acceptable range.
CONCLUSIONS: EOB-MRI strategy is the most cost-effective strategy for differentiating FNH from HCA in patients with incidentally detected focal liver lesions in a non-cirrhotic liver.
KEY POINTS: • The effectiveness of the three strategies was similar. • The cost of the EOB-MRI strategy was lowest. • EOB-MRI strategy is the most cost-effective for differentiating FNH from HCA.
引用
- Suh CH, Kim KW, Park SH, et al. A cost-effectiveness analysis of the diagnostic strategies for differentiating focal nodular hyperplasia from hepatocellular adenoma. Eur Radiol. 2017. PMID: 28726119. doi:10.1007/s00330-017-4967-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。